BriaCell regains Nasdaq minimum bid price compliance; delisting risk resolved

BriaCell Therapeutics Corp.

Received Nasdaq notice of compliance with $1.00 minimum bid price requirement on Feb 12, 2025.
Deficiency letter previously received on August 22, 2024; now resolved.
Matter is closed; company continues listing on Nasdaq Capital Market.
Common shares (BCTX) and warrants (BCTXW) remain eligible for trading.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.